Biological Products, (No Diagnostic Substances)
Standard Industrial Classification: SIC 2836
Industry Insider Sentiment Analysis
The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-21 20:05 | 2026-08-20 | HUMA | Humacyte, Inc. | Jones Keith Anthony | Director | BUY | $0.69 | 10,000 | $6,930 | 40,000 |
| 2026-08-21 20:03 | 2026-08-20 | IMVT | Immunovant, Inc. | Gloria Melanie | Officer | SELL | $44.16 | 3,056 | $134,953 | 219,301 |
| 2026-08-21 20:05 | 2026-08-19 | TWST | Twist Bioscience Corp | Cho Dennis | Officer | SELL | $129.75 | 14,205 | $1,843,099 | 75,661 |
| 2026-08-21 23:22 | 2026-08-20 | GILD | GILEAD SCIENCES, INC. | Bluestone Jeffrey | Director | OPT+S | $145.02 | 5,000 | $725,078 | 10,066 |
| 2026-08-21 23:10 | 2026-08-20 | NMRA | Neumora Therapeutics, Inc. | Aurora Daljit Singh | Officer | OPT+S | $1.53 | 176,060 | $269,970 | 0 |
| 2026-08-21 20:06 | 2026-08-20 | RGEN | REPLIGEN CORP | Loeillot Olivier | Director, Officer | OPT+S | $180.00 | 5,426 | $976,680 | 54,246 |
| 2026-08-21 20:06 | 2026-08-19 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | Director, Officer | OPT+S | $15.75 | 69,076 | $1,088,272 | 825,819 |
| 2026-08-20 21:55 | 2026-08-18 | ADPT | Adaptive Biotechnologies Corp | HERSHBERG ROBERT | Director | OPT+S | $24.40 | 30,664 | $748,208 | 46,683 |
| 2026-08-20 21:00 | 2026-08-18 | PROK | PROKIDNEY CORP. | Pereira Brian JG | Director | SELL | $1.41 | 757,164 | $1,067,753 | 0 |
| 2026-08-20 20:05 | 2026-08-18 | TWST | Twist Bioscience Corp | Finn Patrick John | Officer | OPT+S | $117.64 | 78,355 | $9,217,604 | 214,678 |
| 2026-08-19 20:00 | 2026-08-17 | HUMA | Humacyte, Inc. | Jones Keith Anthony | Director | BUY | $0.59 | 30,000 | $17,820 | 30,000 |
| 2026-08-20 01:00 | 2026-08-18 | ARTV | Artiva Biotherapeutics, Inc. | Banerjee Subhashis | Officer | OPT+S | $12.00 | 429 | $5,148 | 144,963 |
| 2026-08-20 00:15 | 2026-08-17 | ADPT | Adaptive Biotechnologies Corp | ROBINS CHAD M | Director, Officer | OPT+S | $24.80 | 600,000 | $14,882,160 | 2,180,518 |
| 2026-08-20 00:01 | 2026-08-17 | HALO | HALOZYME THERAPEUTICS, INC. | Torley Helen | Director, Officer | OPT+S | $104.59 | 60,000 | $6,275,592 | 767,780 |
| 2026-08-20 00:07 | 2026-08-17 | ADPT | Adaptive Biotechnologies Corp | NEUPERT PETER M | Director | OPT+S | $25.15 | 124,690 | $3,135,854 | 130,625 |
| 2026-08-19 23:17 | 2026-08-17 | NMRA | Neumora Therapeutics, Inc. | Aurora Daljit Singh | Officer | OPT+S | $1.55 | 277,773 | $431,687 | 0 |
| 2026-08-19 22:42 | 2026-08-17 | REPL | Replimune Group, Inc. | Hill Emily Luisa | Officer | SELL | $14.28 | 9,256 | $132,176 | 215,852 |
| 2026-08-19 21:00 | 2026-08-18 | LXEO | Lexeo Therapeutics, Inc. | Otero Jose Manuel | Officer | SELL | $4.96 | 1,304 | $6,464 | 136,178 |
| 2026-08-19 21:00 | 2026-08-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | Director, Officer | SELL | $4.95 | 3,345 | $16,562 | 374,472 |
| 2026-08-19 21:00 | 2026-08-18 | LXEO | Lexeo Therapeutics, Inc. | Tamayo Louis Edward | Officer | SELL | $4.91 | 4,117 | $20,203 | 92,907 |
| 2026-08-19 20:30 | 2026-08-17 | CADL | Candel Therapeutics, Inc. | Tyagarajan Seshu | Officer | SELL | $12.00 | 7,000 | $84,000 | 76,865 |
| 2026-08-18 20:17 | 2026-08-17 | RLAY | Relay Therapeutics, Inc. | Patel Sanjiv | Director, Officer | SELL | $20.33 | 48,199 | $979,886 | 567,699 |
| 2026-08-18 20:16 | 2026-08-14 | RLAY | Relay Therapeutics, Inc. | Catinazzo Thomas | Officer | SELL | $19.74 | 17,717 | $349,734 | 140,568 |
| 2026-08-18 20:30 | 2026-08-14 | CGON | CG Oncology, Inc. | POST LEONARD E | Director | OPT+S | $74.54 | 1,000 | $74,540 | 0 |
| 2026-08-19 01:03 | 2026-08-18 | MGTX | MeiraGTx Holdings plc | Forbes Alexandria | Director, Officer | SELL | $13.86 | 62,000 | $859,320 | 1,325,695 |
| 2026-08-19 00:10 | 2026-08-17 | IVVD | Invivyd, Inc. | Allen Robert D. III | Officer | OPT+S | $0.78 | 37,722 | $29,295 | 178,765 |
| 2026-08-19 00:10 | 2026-08-17 | IVVD | Invivyd, Inc. | Andersen Jill | Officer | OPT+S | $0.78 | 67,962 | $52,779 | 283,774 |
| 2026-08-19 00:10 | 2026-08-17 | IVVD | Invivyd, Inc. | Duke William E. | Officer | OPT+S | $0.78 | 40,780 | $31,670 | 168,937 |
| 2026-08-19 00:10 | 2026-08-17 | IVVD | Invivyd, Inc. | Green Julie | Officer | OPT+S | $0.78 | 40,780 | $31,670 | 168,937 |
| 2026-08-19 00:10 | 2026-08-17 | IVVD | Invivyd, Inc. | Lee Timothy Edward | Officer | OPT+S | $0.78 | 40,780 | $31,670 | 178,937 |
| 2026-08-18 22:54 | 2026-08-17 | GILD | GILEAD SCIENCES, INC. | Mercier Johanna | Officer | OPT+S | $137.64 | 28,000 | $3,853,909 | 118,234 |
| 2026-08-18 23:06 | 2026-08-17 | GILD | GILEAD SCIENCES, INC. | Dickinson Andrew D | Officer | SELL | $138.36 | 3,000 | $415,080 | 165,646 |
| 2026-08-18 16:14 | 2026-08-17 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer | BUY | $0.93 | 5,400 | $5,022 | 381,115 |
| 2026-08-18 00:49 | 2026-08-17 | TNYA | Tenaya Therapeutics, Inc. | Tingley Whittemore | Officer | SELL | $0.71 | 7,424 | $5,270 | 214,073 |
| 2026-08-18 00:50 | 2026-08-17 | TNYA | Tenaya Therapeutics, Inc. | Ali Faraz | Director, Officer | SELL | $0.71 | 22,232 | $15,778 | 417,782 |
| 2026-08-17 21:34 | 2026-08-13 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | Officer | OPT+S | $12.10 | 3,270 | $39,567 | 8,617 |
| 2026-08-14 20:05 | 2026-08-12 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer | OPT+S | $125.08 | 19,952 | $2,495,508 | 818,938 |
| 2026-08-14 20:12 | 2026-08-12 | TWST | Twist Bioscience Corp | BLAKE KATRYN | Director | SELL | $122.88 | 2,240 | $275,251 | 17,208 |
| 2026-08-14 20:05 | 2026-08-12 | VCEL | Vericel Corp | MCLAUGHLIN KEVIN F | Director | OPT+S | $44.53 | 7,000 | $311,710 | 18,300 |
| 2026-08-15 00:57 | 2026-08-14 | OTLK | Outlook Therapeutics, Inc. | Jahr Robert Charles | Director, Officer | BUY | $0.00 | 151,515 | $0 | 151,515 |
| 2026-08-14 23:52 | 2026-08-12 | OTLK | Outlook Therapeutics, Inc. | Sukhtian Ghiath M. | Director, 10% owner | BUY | $0.99 | 2,525,252 | $2,499,999 | 24,617,320 |
| 2026-08-14 23:39 | 2026-08-14 | OTLK | Outlook Therapeutics, Inc. | KENYON LAWRENCE A | Director, Officer | BUY | $0.00 | 101,010 | $0 | 106,956 |
| 2026-08-14 23:25 | 2026-08-12 | TECX | Tectonic Therapeutic, Inc. | McNamara Peter | Officer | OPT+S | $35.00 | 43 | $1,505 | 55,285 |
| 2026-08-14 22:22 | 2026-08-14 | KRYS | Krystal Biotech, Inc. | ROSSI DINO A | Director | SELL | $329.12 | 25,000 | $8,227,953 | 50,000 |
| 2026-08-14 21:00 | 2026-08-13 | CGEM | Cullinan Therapeutics, Inc. | Michaelson Jennifer | Officer | OPT+S | $20.26 | 30,000 | $607,800 | 162,844 |
| 2026-08-14 20:54 | 2026-08-13 | MAZE | Maze Therapeutics, Inc. | Bernstein Harold | Officer | OPT+S | $27.61 | 16,142 | $445,621 | 0 |
| 2026-08-14 01:51 | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | GOLDMAN SACHS GROUP INC | SELL | $21.28 | 105,807 | $2,251,658 | 0 | |
| 2026-08-14 01:51 | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | GOLDMAN SACHS GROUP INC | BUY | $17.58 | 585,000 | $10,285,002 | 3,020,632 | |
| 2026-08-14 01:52 | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | WALSH COLIN | Director | SELL | $21.28 | 105,807 | $2,251,658 | 0 |
| 2026-08-14 01:52 | 2026-08-05 | ATTO | Attovia Therapeutics, Inc. | WALSH COLIN | Director | BUY | $17.58 | 585,000 | $10,285,002 | 3,020,632 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Biological Products, (No Diagnostic Substances)
Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.